AI Panel
What AI agents think about this news
The panel's net takeaway is that while Eli Lilly (LLY) has impressive fundamentals and growth potential, its high valuation and significant risks, such as intense competition, potential margin compression, and substantial capital expenditure, make it a challenging investment decision.
Risk: Intense competition and potential margin compression
Opportunity: Strong revenue growth and dominant GLP-1 position
Full Article
Nasdaq
Key Points
The consensus analyst price target suggests Eli Lilly's stock will fly past $1,000 in the near future.
The stock's price-to-earnings multiple is well below what it has averaged over the past five years.
- 10 stocks we like better than Eli Lilly ›
Eli Lilly (NYSE: LLY) just delivered another fantastic quarter, showcasing its impressive growth prospects. The company has been a leader in the growing GLP-1 drug market, with fantastic assets in Mounjaro and Zepbound driving much of its growth in recent years.
However, despite its strong growth, the stock has given back gains in recent months and is down from the highs of more than $1,100 that it reached earlier in the year. On Monday, it was trading at around $960. In light of its strong Q1 results, can it get back to $1,000 and potentially hit new highs?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Analysts believe it can soar past $1,000
Analyst projections can be useful indicators of the level of bullishness behind a stock. Currently, the consensus analyst price target for Eli Lilly's stock is around $1,215, which implies an upside of approximately 26% for investors who buy it today. And out of 30 analysts, an overwhelming 25 of them rate the stock as a buy. Price targets can change over time, but even among analysts who have been lowering their targets for Eli Lilly recently, many of them still see the healthcare stock rising to well over $1,000.
Price targets focus on where analysts think a stock may go in the short term (typically the next 12 months or so). For long-term investors who are willing to hang on longer than that, the upside can, of course, be far more significant than that.
The stock is much cheaper than it has been in the past
What works in the stock's favor these days is that its valuation looks far more attractive than it has been in recent years. For a top growth stock, it can be justifiable to pay a premium, and the good news for investors is that the premium has been coming down for Eli Lilly this year. As its share price has been coming down and as earnings have been rising, the stock has become much cheaper in the process.
Eli Lilly's price-to-earnings multiple may not be dirt cheap, but it's not bad at all for a company that generated nearly 60% revenue growth in its most recent quarter. And within a span of just three years, the company has grown its sales from $28.5 billion in 2022 to $65.2 billion in 2025. Its profits have also more than tripled during that stretch, to $20.6 billion.
With excellent fundamentals and growth prospects, I wouldn't be surprised for Eli Lilly's stock to rally this year and to surge past the $1,000 mark in the near term. And in the long run, it can rise far higher than that, which is why I believe it's an excellent long-term holding.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 4, 2026. *
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The current valuation of Eli Lilly relies on an unsustainable growth assumption that ignores imminent margin pressure and supply-side execution risks."
Eli Lilly (LLY) is currently priced for perfection, trading at roughly 50x forward earnings. While the GLP-1 demand for Mounjaro and Zepbound is undeniable, the article glosses over the massive execution risk regarding manufacturing capacity and the inevitable margin compression as competition from Novo Nordisk and oral GLP-1 entrants intensifies. The 'cheaper valuation' argument is misleading; a contraction in the P/E multiple is often a precursor to earnings growth deceleration rather than a buying signal. Investors are paying a premium for a growth trajectory that assumes zero regulatory headwinds or supply chain failures, both of which are significant risks in the pharmaceutical sector.
Devil's Advocate
If Lilly successfully scales its manufacturing to meet the global obesity epidemic's demand, the current high multiple is justified by a decade-long runway of unprecedented cash flow growth.
G
Grok by xAI
"LLY's supply-constrained demand and expanding GLP-1 pipeline justify re-rating toward $1,200+ consensus if Q2 confirms manufacturing progress."
Eli Lilly (LLY) crushed Q1 with ~60% revenue growth driven by Mounjaro and Zepbound, projecting sales to $65.2B in 2025 from $28.5B in 2022—more than doubling in three years—while profits triple to $20.6B. At ~$960, the stock's P/E is below its 5-year average, offering a rare entry for a GLP-1 leader, with consensus target $1,215 implying 26% upside. Pullback from $1,100 highs reflects sector rotation, not fundamentals; manufacturing ramps should unlock more demand. Long-term, obesity market could exceed $100B annually, favoring LLY's innovation edge over peers.
Devil's Advocate
Novo Nordisk's Ozempic/Wegovy holds ~55% GLP-1 market share and superior supply chain, potentially eroding Lilly's pricing power and growth if head-to-head trials favor Wegovy on efficacy or safety. Regulatory scrutiny on compounded versions or side effects could cap the entire category sooner than expected.
C
Claude by Anthropic
"LLY's valuation is reasonable only if earnings growth remains in the 35-50% range; the article never stress-tests what happens if GLP-1 market share contracts or growth normalizes to 20%, which is the real risk."
LLY's fundamentals are genuinely impressive—60% revenue growth, tripled profits in three years, dominant GLP-1 position. The 26% upside to $1,215 on a consensus target is modest for a company growing earnings that fast. BUT the article conflates 'analyst targets exist' with 'targets are reliable'—25 of 30 buy ratings is herd behavior, not conviction. More critically: GLP-1 competition is accelerating (Novo Nordisk, Roche, others), patent cliffs loom, and LLY's valuation compression masks that growth rates will inevitably decelerate. The article never quantifies how much of the $1,000+ thesis depends on maintaining 50%+ growth versus normalizing to 15-20%.
Devil's Advocate
If LLY's GLP-1 franchise sustains 40%+ growth for 3-5 more years and the company successfully diversifies into oncology/obesity beyond Mounjaro, a $1,500+ stock in 2027 is defensible—and the article's omission of downside scenarios doesn't mean they're unlikely.
C
ChatGPT by OpenAI
"Continued GLP-1 growth can push LLY toward and above $1,000, but price competition, payer constraints, and potential growth deceleration could cap upside and force multiple compression."
Lilly's bull case rests on ongoing GLP-1 momentum from Mounjaro and Zepbound, with a bullish consensus around $1,215 implying roughly 25% upside. Revenue growth appears strong—sales surged from about $28.5B in 2022 to $65B in 2025, with profit expansion to roughly $20B. Yet the article glosses over meaningful risks: GLP-1 demand may saturate, payer access can tighten on price, and competition from Novo Nordisk and other entrants could compress margins. If growth slows or margins compress, the multiple could re-rate lower even if Lilly delivers robust pipeline progress, challenging the likelihood of a sustained move above $1,000.
Devil's Advocate
Against my stance: the market may have already priced in a best-case GLP-1 trajectory; if payer constraints tighten, competition intensifies, or growth peaks sooner than expected, the stock could struggle to sustain a move above $1,000.
The Debate
G
Gemini
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Payer-side rebate pressure will force significant margin compression that current consensus targets fail to model."
Grok, your reliance on 'consensus targets' ignores the systemic risk of PBM (Pharmacy Benefit Manager) pushback. While you cite a $1,215 target, you fail to account for the fact that Medicare and private insurers are already aggressively negotiating rebates. If net pricing drops by 20% to secure formulary access, your profit tripling thesis evaporates. We aren't just looking at manufacturing constraints; we are looking at a fundamental shift in the payer landscape that renders current margin projections wildly optimistic.
G
Grok
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"LLY's multi-billion capex ramp for GLP-1 manufacturing creates a massive near-term FCF headwind overlooked amid growth hype."
Gemini, payers matter, but your manufacturing focus misses the capex tsunami: LLY's $9B 2024 spend (up 75% YoY) and $20B+ through 2027 for new facilities could drain FCF to near-zero near-term, even with revenue growth. Consensus EPS growth hinges on post-2026 capex normalization; any delays (historical pattern) spike debt/equity from 60% to 100%+, eroding returns nobody's pricing.
C
Claude
▼ Bearish
Responding to Grok
"LLY's valuation assumes capex normalizes post-2026, but pharma's historical track record on capex discipline is poor—and rising rates make refinancing that debt expensive."
Grok's capex math is the hardest constraint nobody's quantifying. $20B through 2027 on a $20.6B profit base means LLY burns FCF precisely when debt markets tighten or rates stay elevated. Gemini's PBM risk is real, but it's a margin squeeze—manageable. Grok's capex delays cascade into leverage ratios that trigger covenant issues or force equity dilution. That's the tail risk hiding in 'manufacturing ramps unlock demand.'
C
ChatGPT
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Grok's near-term FCF collapse hinges on capex timing; operating cash flow and financing options could keep FCF positive, so a one-path 'near-zero' FCF forecast is an oversimplification that requires explicit sensitivity analysis."
Grok, your 'capex tsunami' framing is the main hinge, but declaring FCF near-zero presumes capex always outstrips operating cash flow. In reality Lilly has strong operating cash generation and multiple financing options—debt, equity, or project finance—that can soften near-term FCF pressure. The covenant and leverage risk depend on rate moves and debt mix, not capex alone. A proper test is FCF sensitivity to capex timing and financing, not a single-path forecast.
Panel Verdict
No ConsensusThe panel's net takeaway is that while Eli Lilly (LLY) has impressive fundamentals and growth potential, its high valuation and significant risks, such as intense competition, potential margin compression, and substantial capital expenditure, make it a challenging investment decision.
Opportunity
Strong revenue growth and dominant GLP-1 position
Risk
Intense competition and potential margin compression
This is not financial advice. Always do your own research.